Shilpa Medicare Limited (SHILPAMED.NS)
INR 655.65
(2.46%)
INR 655.65
(2.46%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.44 Billion INR | 7.85% |
| 2022 | 3.19 Billion INR | -9.97% |
| 2021 | 3.55 Billion INR | 12.12% |
| 2020 | 3.16 Billion INR | 39.93% |
| 2019 | 2.26 Billion INR | 20.66% |
| 2018 | 1.87 Billion INR | -0.55% |
| 2017 | 1.88 Billion INR | -0.58% |
| 2016 | 1.89 Billion INR | 16.79% |
| 2015 | 1.62 Billion INR | 24.26% |
| 2014 | 1.3 Billion INR | 6.11% |
| 2013 | 1.23 Billion INR | 65.81% |
| 2012 | 743.32 Million INR | 10.42% |
| 2011 | 673.2 Million INR | 55.36% |
| 2010 | 433.31 Million INR | -14.08% |
| 2009 | 504.34 Million INR | 57.16% |
| 2008 | 320.9 Million INR | -1.26% |
| 2007 | 324.99 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 3.44 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 3.44 Billion INR | 7.85% |
| 2023 Q2 | 3.31 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 3.19 Billion INR | -9.97% |
| 2022 Q4 | 3.19 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 3.63 Billion INR | 0.0% |
| 2021 FY | 3.55 Billion INR | 12.12% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 3.55 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 3.47 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 3.16 Billion INR | 39.93% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 3.16 Billion INR | 0.0% |
| 2020 Q2 | 2.95 Billion INR | 0.0% |
| 2019 FY | 2.26 Billion INR | 20.66% |
| 2019 Q2 | 2.04 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 2.26 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q4 | 1.87 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 2.02 Billion INR | 0.0% |
| 2018 FY | 1.87 Billion INR | -0.55% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 FY | 1.88 Billion INR | -0.58% |
| 2017 Q4 | 1.88 Billion INR | 0.0% |
| 2017 Q2 | 2.33 Billion INR | 0.0% |
| 2016 Q2 | 1.8 Billion INR | 0.0% |
| 2016 Q4 | 1.89 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 1.89 Billion INR | 16.79% |
| 2015 Q4 | 1.62 Billion INR | 0.0% |
| 2015 Q2 | 1.63 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 1.62 Billion INR | 24.26% |
| 2014 Q4 | 1.3 Billion INR | 0.0% |
| 2014 FY | 1.3 Billion INR | 6.11% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.05 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 FY | 1.23 Billion INR | 65.81% |
| 2013 Q2 | 967.65 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 1.23 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 FY | 743.32 Million INR | 10.42% |
| 2012 Q4 | 743.32 Million INR | 0.0% |
| 2012 Q2 | 731.66 Million INR | 0.0% |
| 2011 FY | 673.2 Million INR | 55.36% |
| 2011 Q4 | 673.2 Million INR | 0.0% |
| 2010 FY | 433.31 Million INR | -14.08% |
| 2009 FY | 504.34 Million INR | 57.16% |
| 2008 FY | 320.9 Million INR | -1.26% |
| 2007 FY | 324.99 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Hester Biosciences Limited | 755.81 Million INR | -356.369% |
| RPG Life Sciences Limited | 1.01 Billion INR | -241.513% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | -49.193% |
| Ipca Laboratories Limited | 24.71 Billion INR | 86.043% |
| Aarti Drugs Limited | 4.85 Billion INR | 29.011% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 46.345% |
| Albert David Limited | 436.12 Million INR | -690.9% |
| Alembic Limited | 113.4 Million INR | -2941.694% |
| Alkem Laboratories Limited | 26.61 Billion INR | 87.039% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 79.013% |
| Bafna Pharmaceuticals Limited | 296.41 Million INR | -1063.654% |
| Bajaj HealthCare Limited | 1.44 Billion INR | -139.47% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -13428.184% |
| Brooks Laboratories Limited | 96.1 Million INR | -3488.963% |
| Eris Lifesciences Limited | 1.89 Billion INR | -82.471% |
| FDC Limited | 3.88 Billion INR | 11.304% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 48.255% |
| Gufic Biosciences Limited | 2 Billion INR | -72.049% |
| Hikal Limited | 3.03 Billion INR | -13.568% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -3198.317% |
| Ind-Swift Limited | 640.91 Million INR | -438.181% |
| Innova Captab Limited | 1.44 Billion INR | -139.507% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 18.81% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -2199.981% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 73.253% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -8549.15% |
| Laurus Labs Limited | 18.45 Billion INR | 81.309% |
| Lincoln Pharmaceuticals Limited | 771.68 Million INR | -346.983% |
| Lupin Limited | 49.53 Billion INR | 93.037% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | -178.978% |
| Medico Remedies Limited | 163.37 Million INR | -2011.305% |
| Morepen Laboratories Limited | 2.48 Billion INR | -38.751% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 51.36% |
| Orchid Pharma Limited | 2.64 Billion INR | -30.543% |
| Procter & Gamble Health Limited | 1.09 Billion INR | -216.129% |
| Sigachi Industries Limited | 707.2 Million INR | -387.733% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 4.107% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 96.505% |
| Themis Medicare Limited | 705.74 Million INR | -388.745% |
| Unichem Laboratories Limited | 7.04 Billion INR | 51.052% |
| Vaishali Pharma Limited | 3.79 Million INR | -90742.27% |
| Venus Remedies Limited | 1.21 Billion INR | -183.448% |
| Wanbury Limited | 360.23 Million INR | -857.517% |
| Windlas Biotech Limited | 621.89 Million INR | -454.645% |
| ZIM Laboratories Limited | 812.62 Million INR | -324.46% |
| Sakar Healthcare Limited | 277.32 Million INR | -1143.777% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 96.483% |
| Divi's Laboratories Limited | 31.84 Billion INR | 89.167% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | -51.363% |
| Mankind Pharma Limited | 15.53 Billion INR | 77.796% |
| Sequent Scientific Limited | 3.46 Billion INR | 0.377% |
| Neuland Laboratories Limited | 3.5 Billion INR | 1.568% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 31.359% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 86.275% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 89.979% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -1093.329% |
| Wockhardt Limited | 6.4 Billion INR | 46.105% |
| Bal Pharma Limited | 878.11 Million INR | -292.806% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 94.573% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | -191.208% |
| Par Drugs and Chemicals Limited | 41.77 Million INR | -8157.795% |
| Caplin Point Laboratories Limited | 3.63 Billion INR | 4.989% |
| Valiant Laboratories Limited | 100.15 Million INR | -3343.977% |
| Ajanta Pharma Limited | 8.28 Billion INR | 58.36% |
| Aarey Drugs & Pharmaceuticals Limited | 346.75 Million INR | -894.725% |
| Granules India Limited | 13 Billion INR | 73.478% |
| Medicamen Biotech Limited | 593.75 Million INR | -480.93% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -1536.165% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 84.865% |
| NATCO Pharma Limited | 7 Billion INR | 50.76% |
| Suven Life Sciences Limited | 7.08 Million INR | -48584.277% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -3420.968% |
| Strides Pharma Science Limited | 11.26 Billion INR | 69.373% |
| Indoco Remedies Limited | 3.53 Billion INR | 2.303% |
| Alpa Laboratories Limited | 136.65 Million INR | -2424.117% |
| Lasa Supergenerics Limited | 190.43 Million INR | -1711.274% |
| Sun Pharma Advanced Research Company Limited | 14.79 Million INR | -23218.557% |